百度设3亿人币基金结合AI大数据支持药物研发
百度创办人李彦宏表示,公司成立3亿元人民币的专项基金,结合百度的人工智能(AI)、大数据能力,支持抗击疫情的新药筛选和研发,以及更长期的社会公共卫生安全信息科普和传播等。
据悉,针对支持新型冠状病毒等新疾病的治愈药物筛选、研发等一系列抗击疫情工作,百度将提供人工智能技术支持,配套亿级计算资源,助力疾控机构、科研院所等研究单位进行研发提速。同时,百度将提供时空大数据及分析技术,支持对疫情的及时发现、快速应对及科学管理。
李彦宏在内部信中提到,在抵抗疫情、推进药物研发之外,强化公众的卫生安全意识也是此次战疫乃至未来公共卫生安全维护的重中之重,支持从根本上去解决社会公共卫生安全意识缺失的问题。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.